Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2013Título de revista
ARTHRITIS AND RHEUMATISM
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)